New study sheds light on potential treatment for Gaucher’s diseaseMay 10th, 2010 - 3:47 pm ICT by ANI
London, May 10 (ANI): Scientists at The Scripps Research Institute have shed light on a mechanism that enables a potential treatment for Gaucher’s disease and other lysosomal storage diseases.
In the new study, the researchers revealed how the widely available prescription drugs diltiazem, verapamil, and in some cases dantrolene, acted on cells from patients with Gaucher’s disease.
The drugs increased calcium levels in a subcellular compartment called the endoplasmic reticulum-a convoluted membranous sac within the cell where the folding of many proteins takes place.
“This study is likely to motivate clinical trials for the treatment of neuropathic lysosomal storage diseases, including Gaucher’s disease, where the current standard of care, enzyme replacement therapy, is ineffective,” Nature quoted team leader Dr. Jeffery Kelly, as saying.
“The research is especially promising because we enhanced the cellular folding and function of mutated lysosomal enzymes, whose deficient function is linked to lysosomal storage diseases, using two distinct categories of FDA-approved drugs that have been shown to be safe and effective for the treatment of high blood pressure and muscle spasms,” he added.
“We wanted to uncover general principles that could be applied to a variety of loss-of-function protein misfolding diseases. This study reveals how we can enhance the capacity of the cellular machinery to fold and traffic a mutant enzyme, so that the protein can function better,” said Derrick Sek Tong Ong, first author of the paper.
Gaucher’s disease is the most common genetic disease among the Ashkenazi Jewish population of Eastern European ancestry.
Symptoms include bruising easily due to low blood platelets, enlargement of the liver and spleen, and fatigue due to anaemia.
In the new paper, the lab found that the prescription drugs diltiazem and verapamil were effective in restoring partial cellular folding, trafficking, and function to mutant enzymes responsible for three lysosomal storage disorders, including Gaucher’s disease.
The findings were published in an advance, online edition of the journal Nature Chemical Biology. (ANI)
- Scientists reveal new clues to origin of diabetes - Oct 13, 2010
- Model shows promise to develop therapies for protein folding diseases - Apr 28, 2011
- How protein folding could cure Alzheimer, Parkinson diseases - Mar 21, 2011
- She fights genetic disorder with art (Feature) - Sep 24, 2011
- How misfolded protein spreads from cell to cell, potentially spreading disease - Feb 19, 2011
- New mechanism links cellular stress to brain damage - Dec 09, 2010
- Faulty clean-up process may be Huntington's disease key - Apr 12, 2010
- 'Early diagnosis can save patients with genetic disorders' - May 15, 2012
- New compounds may help develop drugs for degenerative nerve diseases - Jan 20, 2010
- Misfolding neural proteins linked with autism - Sep 13, 2010
- Potential treatment for Huntington's disease found - Nov 16, 2009
- Misfolded neural proteins linked to autism disorders identified - Sep 11, 2010
- Scientists find way to harness thrombin's anti-blood clotting properties - Jun 21, 2010
- New method to turn blood-brain barrier into therapy delivery system - Sep 22, 2009
- Inadequate sleep may exacerbate cellular aging in older adults - Jun 28, 2008
Tags: blood platelets, calcium levels, cellular machinery, common genetic disease, dantrolene, diltiazem, distinct categories, enlargement of the liver, enzyme replacement therapy, european ancestry, fda approved drugs, high blood pressure, jewish population, lysosomal storage diseases, membranous sac, prescription drugs, protein misfolding, scripps research institute, treatment of high blood pressure, verapamil